Latest IBD Stories

Treating children with inflammatory bowel disease (IBD) usually involves the same steroids-based medication prescribed to adults. But such treatments can have negative side effects for kids and teens dealing with IBD.Dr. Raanan Shamir of Tel Aviv University's Sackler School of Medicine and Schneider Children's Medical Centre shows that there is another path to treating IBD in children: a nutritional formula that was first developed for astronauts. This supplement puts 60-70% of children...

Researchers at Penn State College of Medicine, working with biochemists, geneticists and clinicians at the University of Bern, Switzerland and in the United Kingdom, have discovered an enzyme that has a key role in inflammatory bowel disease (IBD). The team, co-led by Judith Bond, Ph.D., Distinguished Professor and Chair of Biochemistry and Molecular Biology at Penn State College of Medicine, and Daniel Lottaz, Department of Rheumatology and Clinical Immunology at the University of Bern,...

New Insights into the Prediction of IBD Using Serology Testing Also Presented SAN DIEGO, June 2 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announced new findings regarding a correlation between an important serologic marker used in the detection of Crohn's disease and particular genetic markers in patients at risk for celiac disease. In an oral presentation yesterday at Digestive Disease Week (DDW) in Chicago, Prometheus reported a...

 Researchers are making great strides in understanding the development and treatment of inflammatory bowel disease, a chronic inflammatory condition of the digestive tract that affects more than a half million Americans, according to several studies being presented at Digestive Disease Week® 2009 (DDW®). DDW is the largest international gathering of physicians and researchers in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery.Inflammatory bowel...

First-in-class Oral Therapeutic for IBD with Novel Mode of Action MOUNTAIN VIEW, Calif., May 19 /PRNewswire/ -- ChemoCentryx, Inc., today announced that data from the company's PROTECT-1 (the Prospective Randomized Oral Therapy Evaluation in Crohn's disease Trial) Phase II/III clinical trial of Traficet-EN(TM) (CCX282-B) in patients with moderate-to-severe Crohn's disease will be presented in an oral session at the upcoming 2009 Digestive Disease Week (DDW) meeting. Traficet-EN is an...

Developed by a Crohn's patient with help from GI specialists, GI Monitor, an iPhone App launched by WellApps, Inc., allows patients with (IBD) Crohn's and Ulcerative Colitis to track their symptoms and deliver accurate data to their doctors. UPPER SADDLE RIVER, N.J., May 19 /PRNewswire/ -- WellApps, Inc. launched an iPhone application to help people with (IBD) Crohn's and Ulcerative Colitis provide accurate symptom data to their doctors for optimal treatment. The application, called GI...

Virtual March Connects 'IBD Day on the Hill' Advocates in Washington, D.C. with Online Supporters PHILADELPHIA, May 6 /PRNewswire-FirstCall/ -- Today the Crohn's & Colitis Foundation of America (CCFA) and Shire plc (LSE: SHP, Nasdaq: SHPGY) joined forces to launch the first-ever virtual "Inflammatory Bowel Disease (IBD) March on the Hill." The free program calls on Facebook(R) users to help raise awareness of IBD and spurs funds for additional research of the disease. To participate...

A team of scientists at The Scripps Research Institute has linked a mouse mutation to an increased susceptibility for developing inflammatory bowel disease -- represented in humans as Crohn's disease and ulcerative colitis, which together are estimated to affect more than a million people in the United States. The findings may one day lead to new and better treatments for the disease.The work was published in the February 6, 2009 Early Edition of the Proceedings of the National Academy of...

Simultaneous Studies to Investigate Novel Therapy for Ulcerative Colitis and Crohn's Disease OSAKA, Japan, Jan. 22 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") announced today that its wholly-owned subsidiary, Millennium Pharmaceuticals, Inc., has initiated two Phase III clinical trials for vedolizumab (MLN0002), an investigational compound for inflammatory bowel disease (IBD). The trials, known as the GEMINI(TM) program, will study vedolizumab for the treatment of...

Discovery could improve understanding of disease process, lead to new therapiesAn international team led by University of Pittsburgh School of Medicine researchers has identified genetic markers associated with risk for ulcerative colitis. The findings, which appear today as an advance online publication of the journal Nature Genetics, bring researchers closer to understanding the biological pathways involved in the disease and may lead to the development of new treatments that specifically...